Company profile
Exelixis, Inc.
NASDAQ: EXEL · Healthcare · Biotechnology
#105 of 1,422 Healthcare companies by revenue52nd-percentile growth
EA Score
89AFH 93DQ 94GM 64SS 89
v0.1 · 65/100 weight · provisional
↑ operating margin, return on assets · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$2.4B
Rev growth YoY (TTM)
+3.3%
Net income (FY)
$782.6M
Employees
1,077
as of 2026-08-05
Market cap
$14.1B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.3B$2.3B2025
Net income$782.6M$782.6M2025
Operating income$872.2M$872.2M2025
Total assets$2.8B$2.8B2025
Liabilities$683.1M$683.1M2025
Equity$2.2B$2.2B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product, Gross65%
Product46%
License5%
Collaboration4%
Service-0%
Product, Sales Discounts And Allowances-19%
By geography
UNITED STATES92%
Europe7%
JAPAN1%
The read
What is Exelixis, Inc.’s revenue?
Exelixis, Inc. booked $2.3B in FY2025 revenue, growing 7.0% year over year — about the middle of the pack among Healthcare companies we track, at a 33.7% net margin.
Peers · Healthcare
Aveanna Healthcare Holdings Inc.66BRoyalty Pharma plc72BHims & Hers Health, Inc.68BNatera, Inc.75B+Enovis Corporation66BICU Medical, Inc.78B+Neighbors
Alameda →Key facts
CEOMichael Morrissey
SectorHealthcare
IndustryBiotechnology
HeadquartersAlameda, CA
ExchangeNASDAQ: EXEL
Employees1,077
IPO date2000-04-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.